Moesin activation controls bone resorption and tunneling nanotube-dependent osteoclast fusion

Ophélie Dufrancais, Perrine Verdys,Arnaud Métais, Marie Juzans, Thibaut Sanchez, Martin Bergert, Marianna Plozza,Julia Halper, Christopher J Panebianco,Rémi Mascarau,Rémi Gence, Gaëlle Arnaud,Myriam Ben Neji,Isabelle Maridonneau-Parini, Véronique Le Cabec,Joel D Boerckel,Nathan J Pavlos,Alba Diz-Muñoz, Frédéric Lagarrigue, Claudine Blin-Wakkach, Sébastien Carréno,Renaud Poincloux,Janis K Burkhardt,Brigitte Raynaud-Messina,Christel Vérollet

biorxiv(2024)

Cited 0|Views4
No score
Abstract
Osteoclasts are multinucleated cells unique in their ability to resorb bone. Osteoclastogenesis involves several steps of actin-driven rearrangements that participate not only in the cell-cell fusion process, but also in the formation of the sealing zone, the adhesive structure determining the resorption area. Despite the importance of these actin cytoskeleton-based processes, their precise mechanisms of regulation are still poorly characterized. Here, we found that moesin, a member of the Ezrin/Radixin/Moesin (ERM) protein family, is activated during osteoclast maturation and plays an instrumental role for both osteoclast fusion and function. In mouse and human osteoclast precursors, moesin is negatively regulated to potentiate their ability to fuse and degrade bone. Accordingly, we demonstrated that moesin depletion decreases membrane-to-cortex attachment and enhances formation of tunneling nanotubes (TNTs), F-actin-containing intercellular bridges that we revealed to trigger osteoclast fusion. In addition, via a β3-integrin/RhoA/SLK pathway and independently of its role in fusion, moesin regulates the number and organization of sealing zones in mature osteoclast, and thus participates in the control of bone resorption. Supporting these findings, we found that moesin-deficient mice are osteopenic with a reduced density of trabecular bones and increased osteoclast abundance and activity. These findings provide a better understanding of the regulation of osteoclast biology, and open new opportunities to specifically target osteoclast activity in bone disease therapy. ### Competing Interest Statement The authors have declared no competing interest.
More
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined